Bufuralol Hydrochloride: Non-Selective β-Adrenergic Antagonist in Cardiovascular Disease Research

Executive Summary: Bufuralol hydrochloride (CAS 60398-91-6) is a crystalline small molecule acting as a non-selective β-adrenergic receptor antagonist, with partial intrinsic sympathomimetic activity observed as tachycardia in catecholamine-depleted animal models (APExBIO). It demonstrates membrane-stabilizing effects in vitro and a prolonged inhibitory action on exercise-induced heart rate elevation similar to propranolol (Saito et al., 2025). Its solubility profile is well-defined, with up to 10 mg/ml in DMSO and 15 mg/ml in ethanol or DMF, and it must be stored at -20°C for stability. Bufuralol is frequently employed in cardiovascular pharmacology studies, especially those utilizing advanced human iPSC-derived intestinal organoid models to assess β-adrenergic modulation and pharmacokinetics (see organoid application). This article provides atomic, evidence-based insights for bench scientists integrating bufuralol hydrochloride in disease modeling and β-adrenoceptor pathway research.

Biological Rationale

β-adrenergic receptors (β-ARs) are G protein-coupled receptors central to cardiovascular homeostasis, modulating heart rate, contractility, and vascular tone (Saito et al., 2025). Non-selective β-adrenergic antagonists such as bufuralol hydrochloride block both β1 and β2 subtypes, making them effective tools for dissecting total β-adrenergic signaling in preclinical and translational settings. Bufuralol's partial intrinsic sympathomimetic activity distinguishes it from pure antagonists and is relevant for studies modeling tachycardia and partial agonist phenomena. The integration of bufuralol into human iPSC-derived organoid systems, which recapitulate intestinal absorption and metabolism, enables more predictive pharmacokinetic assessments compared to traditional rodent or cancer-derived cell models (Saito et al., 2025). This supports the use of bufuralol as a probe in both cardiovascular disease research and β-adrenergic modulation studies.

Mechanism of Action of Bufuralol hydrochloride

Bufuralol hydrochloride competitively inhibits β1- and β2-adrenergic receptors, antagonizing the actions of endogenous catecholamines (epinephrine, norepinephrine). In animal models with depleted catecholamine stores, bufuralol induces tachycardia, demonstrating its partial agonist (intrinsic sympathomimetic) activity (APExBIO). In vitro, it also exhibits membrane-stabilizing (local anesthetic-like) effects, which may contribute to its pharmacological profile. Bufuralol's action on β-ARs leads to reduced cAMP production, blunting downstream signaling pathways that mediate positive chronotropic and inotropic cardiac responses. The partial agonist activity is quantifiable in tissue bath assays and animal telemetry studies. These properties make bufuralol valuable for isolating and quantifying β-adrenergic modulation under both physiological and pathological conditions.

Evidence & Benchmarks

• Bufuralol hydrochloride is a non-selective β-adrenergic receptor blocker with partial intrinsic sympathomimetic activity, as measured by its induction of tachycardia in catecholamine-depleted animal models (APExBIO).
• It exhibits a molecular weight of 297.8 Da and chemical formula C16H23NO2·HCl, facilitating precise dosing in in vitro and in vivo experiments (APExBIO).
• Bufuralol displays solubility up to 10 mg/ml in DMSO, 15 mg/ml in ethanol, and 15 mg/ml in dimethyl formamide; solutions should be prepared fresh and stored at -20°C to maintain potency (APExBIO).
• Human iPSC-derived intestinal organoids are validated as advanced models for drug absorption and metabolism studies, offering advantages over Caco-2 and animal models for bufuralol pharmacokinetics (Saito et al., 2025).
• Bufuralol's inhibitory effect on exercise-induced heart rate elevation is prolonged and quantitatively similar to propranolol in controlled human and animal studies (APExBIO).
• For integration with organoid-based workflows, bufuralol has been shown to be a useful probe in experiments measuring cytochrome P450-mediated metabolism and transepithelial transport (Saito et al., 2025).

Applications, Limits & Misconceptions

Bufuralol hydrochloride is primarily used in:

• Cardiovascular pharmacology research to study β-adrenergic modulation and disease models.
• Pharmacokinetic and metabolism studies using hiPSC-derived organoids, which provide human-relevant absorption and metabolic profiles (Saito et al., 2025).
• Assessment of beta-adrenoceptor signaling pathway activity and membrane-stabilizing effects in vitro.
• Comparative studies against other β-blockers such as propranolol to dissect class effects and intrinsic activity.

To explore mechanistic details and scenario-driven guidance, see Bufuralol hydrochloride (SKU C5043): Scenario-Driven Solutions, which addresses real-world challenges and practical experimental design. This article extends those findings by offering a granular, evidence-based summary of solubility, storage, and integration with organoid models.

For detailed workflows and troubleshooting in organoid models, refer to Bufuralol Hydrochloride: Advancing β-Adrenergic Modulation. Here, we clarify specific benchmarks and highlight updated pharmacokinetic model validation using hiPSC-derived organoids.

Common Pitfalls or Misconceptions

• Not a selective β1- or β2-antagonist: Bufuralol blocks both subtypes; do not use where selectivity is essential.
• Partial agonist effect: May induce tachycardia in catecholamine-depleted systems; not suitable as a pure antagonist control (APExBIO).
• Solution stability: Bufuralol solutions degrade; always prepare fresh and avoid long-term storage at room temperature.
• Species differences: Pharmacokinetic data from rodent models may not translate directly to humans due to metabolic and receptor subtype differences (Saito et al., 2025).
• Not a comprehensive membrane stabilizer: While bufuralol has some membrane-stabilizing effects, it is not a substitute for dedicated antiarrhythmic agents.

Workflow Integration & Parameters

Preparation: Dissolve bufuralol hydrochloride in DMSO (up to 10 mg/ml), ethanol, or DMF (up to 15 mg/ml); filter-sterilize if required. Use freshly prepared solutions and store aliquots at -20°C for short-term use (APExBIO).

Application in Organoid Models: Human iPSC-derived intestinal organoids (hiPSC-IOs) can be used as a high-fidelity model for absorption and metabolism. Incubate bufuralol at physiologically relevant concentrations (e.g., 1–10 μM) and monitor metabolism via CYP3A4 and transporter activity (Saito et al., 2025).

Controls: Include propranolol as a benchmark β-blocker and negative controls lacking β-AR activity for comparative analysis.

For deeper exploration of bufuralol's integration with next-generation organoid systems, see Bufuralol Hydrochloride in Next-Gen Pharmacokinetics; this article updates those findings with the latest solubility and storage data from APExBIO.

Reporting: Quantify pharmacodynamic endpoints (e.g., heart rate, cAMP, membrane potential) and metabolic profiles (CYP, transporter assays) under defined conditions (temperature, medium, time).

Conclusion & Outlook

Bufuralol hydrochloride is a validated, non-selective β-adrenergic receptor antagonist with unique partial intrinsic sympathomimetic activity, supported by peer-reviewed and product-based evidence. It is essential in cardiovascular pharmacology research, β-adrenergic modulation studies, and human organoid-based pharmacokinetic modeling. For rigorous, reproducible experiments, researchers should source bufuralol hydrochloride from reputable suppliers such as APExBIO and adhere to best practices for solution preparation and storage. Future directions include leveraging bufuralol in personalized organoid systems and integrated disease models to further unravel beta-adrenoceptor signaling in health and disease.